Joshua Prince appointed COO of Vistagen Therapeutics

Vistagen Therapeutics, Inc.

Joshua Prince appointed Chief Operating Officer effective Oct 24, 2023; had been SVP Business Operations since Nov 2021.
Prince brings over 20 years pharma experience including roles at CSL Behring, Teva, and AstraZeneca.
Holds a BS in Mechanical Engineering from Missouri-Rolla and an MBA from Penn State.
Company entered into standard Indemnification Agreement with Prince for his service.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Joshua Prince

Chief Operating Officer

VTGN · Vistagen Therapeutics, Inc.

Effective: 2023-10-24
Filed: October 26, 2023, 7:59 PM ET

On October 24, 2023, Joshua Prince was appointed to serve as the Chief Operating Officer of Vistagen Therapeutics, Inc. (the “ Company ”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Joshua Prince was appointed as Chief Operating Officer at Vistagen Therapeutics, Inc..

Action: appointed
Role: Chief Operating Officer

Exact text from the filing

On October 24, 2023, Joshua Prince was appointed to serve as the Chief Operating Officer of Vistagen Therapeutics, Inc. (the “ Company ”).

View on SEC.gov

Vistagen Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-029096

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.